Atul Dandekar Sells 7,500 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $28.02, for a total transaction of $210,150.00. Following the completion of the transaction, the insider owned 26,250 shares in the company, valued at $735,525. This trade represents a 22.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, April 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $25.37, for a total transaction of $190,275.00.

Maze Therapeutics Stock Up 4.9%

Shares of MAZE stock opened at $31.26 on Friday. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. Maze Therapeutics, Inc. has a 12 month low of $10.98 and a 12 month high of $53.65. The stock has a market cap of $1.73 billion, a P/E ratio of -12.36 and a beta of 2.14. The company has a 50 day simple moving average of $25.92 and a two-hundred day simple moving average of $35.67.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. On average, research analysts expect that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Hedge Funds Weigh In On Maze Therapeutics

Large investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP bought a new position in shares of Maze Therapeutics in the first quarter worth about $917,000. Bank of America Corp DE lifted its holdings in Maze Therapeutics by 961.3% in the 1st quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock worth $5,823,000 after purchasing an additional 176,703 shares in the last quarter. Royal Bank of Canada lifted its holdings in Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after purchasing an additional 1,383 shares in the last quarter. Exome Asset Management LLC bought a new position in Maze Therapeutics in the 1st quarter worth approximately $2,642,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Maze Therapeutics by 111.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock worth $435,000 after purchasing an additional 7,673 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MAZE. Wedbush upped their price target on Maze Therapeutics from $43.00 to $58.00 and gave the stock an “outperform” rating in a research report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Truist Financial cut their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 14th. BTIG Research reissued a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.